Meeting Information - The annual general meeting for 2024 will be held on June 26, 2025, at 1:00 PM [2] - The meeting will be conducted using a combination of on-site and online voting methods [2] - The physical meeting location is at 601 Meeting Room, Phase II, Fenglin International Building, 450 Fenglin Road, Xuhui District, Shanghai, China [2] Voting Procedures - The online voting system will be the Shanghai Stock Exchange's shareholder meeting online voting system, with voting available from 9:15 AM to 3:00 PM on the day of the meeting [3] - Specific voting times through the trading system are from 9:15 AM to 9:25 AM, 9:30 AM to 11:30 AM, and 1:00 PM to 3:00 PM [3] - Shareholders can vote through either the trading system or the internet voting platform, with identity verification required for first-time users [7] Meeting Agenda - The meeting will review several proposals, with special resolutions numbered 8 to 11 [6] - Proposals 5, 6, 7, 9, and 10 will have separate voting counts for minority investors [7] - There are no proposals requiring abstention from related shareholders [7] Attendance Requirements - Shareholders registered by the close of trading on the registration date are eligible to attend the meeting [11] - Both individual and corporate shareholders must provide specific identification and authorization documents if represented by an agent [14][15] Additional Information - Shareholders are responsible for their own travel and accommodation expenses [16] - Contact information for the company is provided for further inquiries [16]

Meeting Information - The annual general meeting of Shanghai Pharmaceuticals Holding Co., Ltd. is scheduled for June 26, 2025 [1] - The meeting will utilize a combination of on-site and online voting methods [1] - The on-site meeting will take place at 13:00 at Fenglin International Building, Shanghai [1] Voting Procedures - Shareholders can vote through the Shanghai Stock Exchange's online voting system from 9:15 to 15:00 on the day of the meeting [1][2] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [3][4] - Duplicate voting through different methods will be counted based on the first vote cast [4] Attendance Requirements - Shareholders must be registered with the China Securities Depository and Clearing Corporation by the close of trading on June 20, 2025, to attend the meeting [5] - Both individual and corporate shareholders must provide specific identification and authorization documents for attendance [5] Registration Process - On-site registration will occur from 12:00 to 13:00 on June 26, 2025 [5] - Fax registration must be completed by 15:00 on June 25, 2025 [5] Additional Information - Contact details for the board office are provided for further inquiries [6]

证券代码：601607 证券简称：上海医药 公告编号：临2025-059 上海医药集团股份有限公司 关于召开2024年年度股东大会的通知 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024年年度股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 6 月 26 日 13 点 00 分 召开地点：中国上海市徐汇区枫林路 450 号枫林国际大厦二期六楼裙楼 601 会议室 1 股东大会召开日期：2025年6月26日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次股东大会审议议案及投票股东类型 | 序号 | | 议案名称 | 投票股东类型 | | | --- | --- | --- | --- | --- | | | | | A 股股东 | H 股股东 | | | 非累积投票议案 | | | ...

上海医药集团股份有限公司 2024 年年度股东大会 会议文件 股东大会 会议文件 目录 | 2024 年年度股东大会会议议程及注意事项 2 | | | --- | --- | | 释义 3 | | | 一、2024 | 年度报告 4 | | 二、2024 | 年度董事会工作报告 5 | | 三、2024 | 年度监事会工作报告 9 | | 四、2024 | 年度财务决算报告及 2025 年度财务预算报告 12 | | 五、2024 | 年度利润分配预案 16 | | 六、关于续聘会计师事务所的议案 17 | | | 七、关于 | 2025 年度对外担保计划的议案 18 | | 八、关于发行债务融资产品的议案 28 | | | 九、关于公司符合发行公司债券条件的议案 | 32 | | 十、关于公开发行公司债券的议案 33 | | | 十一、关于公司一般性授权的议案 55 | | 二零二五年六月二十六日 1 股东大会 会议文件 现场会议时间：2025 年 6 月 26 日（周四）下午 13:00 会议地点：中国上海市徐汇区枫林路 450 号枫林国际大厦二期六楼裙楼 601 会议室 一、 会议议程 1 1、宣布大会 ...

| 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 上海醫藥集團股份有限公司 | | 股份代號 | 02607 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度之末期股息 (更新） | | 公告日期 | 2025年5月29日 | | 公告狀態 | 更新公告 | | 更新/撤回理由 | 更新股東批准日期 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 10 股 2.9 RMB | | 股東批准日期 | 2025年6月26日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 有待公佈 | | 匯率 ...

股東名稱： 02607 2. 請填上以 閣下名稱登記的股份數目。 H股股東出席 股東週年大會回條 3. 就公司H股持有者而言，此填妥及經簽署的回條須於2025年6月16日或之前透過專人或郵遞送達公司的 H股證券登記處MUFG Corporate Markets Pty Limited，地址為香港中環皇后大道中28號中匯大廈16樓 1601室。公司H股持有人須確保於2025年6月20日16:30前將所有過戶文件連同有關股票送交公司的H股 證券登記處MUFG Corporate Markets Pty Limited（地址為香港中環皇后大道中28號中匯大廈16樓1601 室），以符合資格出席股東週年大會（或其任何續會）並於會上投票。 致：上海醫藥集團股份有限公司（「公司」） 股東名稱及登記地址 （附註1） ： 持股數目 （附註2） : 股H股 本人╱吾等擬親自出席或委任代表出席於2025年6月26日13:00於中國上海市徐匯區楓林路450 號楓林國際大廈二期六樓裙樓601會議室舉行的公司股東週年大會（或其任何續會）。 股東簽署： 日期：2025年 月 日 Shanghai Pharmaceuticals Hold ...

股東週年大會通知 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部分內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 Shanghai Pharmaceuticals Holding Co., Ltd. * 02607 茲通知上海醫藥集團股份有限公司（「本公司」）謹訂於2025年6月26日13:00於中國上海市徐 匯區楓林路450號楓林國際大廈二期六樓裙樓601會議室舉行股東週年大會，以審議及批 准下列事項： 普通決議 特別決議 - 1 - (1) 2024年度報告 (2) 2024年度董事會工作報告 (3) 2024年度監事會工作報告 (4) 2024年度財務決算報告及2025年度財務預算報告 (5) 2024年度利潤分配預案 (6) 關於續聘會計師事務所的議案 (7) 關於2025年度對外擔保計劃的議案 (8) 關於發行債務融資產品的議案 (9) 關於公司符合發行公司債券條件的議案 * 僅供識別 (10) 關於發行公司債券的議案 (11) 關於公司一般性授權的議案 承董事會命 上海醫藥集團股份有限 ...

此乃要件 請即處理 閣下如對本通函任何方面或應採取的行動有任何疑問，應諮詢 閣下的股票經紀或其他註冊證 券商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已將名下的上海醫藥集團股份有限公司的股份全部售出或轉讓，應立即將本通函及隨附 的代表委任表格及回條交予買主或承讓人，或經手買賣或轉讓的銀行、股票經紀或其他代理 商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不會就本通函全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Pharmaceuticals Holding Co., Ltd. * 有關本公司股東週年大會的相關會議通知、適用代表委任表格及回條隨本通函附奉。 就H股持有人而言，無論 閣下能否出席股東週年大會，務請細閱股東週年大會通知。倘 閣 下擬委派代表出席股東週年大會，請按照隨附代表委任表格上印列的指示填妥及交回代表委任 表格。填妥及交回代表委任表格後， 閣下仍可親自出席股東週年大會（或其任何續會），並於 會上投票。 就H股持有人而言，倘 閣下擬親自或委 ...

Summary of M&A Activity in Q1 2025 Core Insights - The M&A market in Q1 2025 saw a total of 534 transactions with a combined value of 2371.86 billion RMB, maintaining a steady volume compared to the same period last year [2][21] - The most active sectors for M&A transactions included traditional industries, smart manufacturing, and energy and power [23][25] Group 1: Transaction Volume and Value - In Q1 2025, there were 421 newly disclosed M&A transactions valued at 1040.28 billion RMB, with 173 completed transactions worth 1282.89 billion RMB [21][23] - Traditional industries led the transaction volume with 94 deals (17.60%), followed by smart manufacturing with 71 deals (13.30%) and energy and power with 48 deals (8.99%) [23][25] Group 2: Sector Analysis - The largest disclosed transaction value was in traditional industries, reaching 190.52 billion RMB, followed by cultural entertainment at 156.09 billion RMB and e-commerce at 119.67 billion RMB [4][25] - Within traditional industries, the most active sub-sectors included traditional manufacturing (35 deals), construction (15 deals), traditional energy (7 deals), and real estate and home furnishings (5 deals) [3][25] Group 3: Regional Distribution - M&A activity was predominantly concentrated in the eastern coastal regions of China, with Guangdong leading with 60 transactions, followed by Jiangsu (49 transactions) and Shanghai (43 transactions) [5][27] - In terms of transaction value, Guangdong also topped the list with 225.39 billion RMB, followed closely by Shanghai at 223.26 billion RMB and Jiangsu at 112.65 billion RMB [5][27] Group 4: Transaction Size and Company Age - The majority of transactions were small, with 70 deals (26.02%) valued at under 10 million RMB, followed by 36 deals in the 200 million to 500 million RMB range [6][29] - Companies established between 5 to 10 years accounted for 25.90% of the M&A targets, with 109 such companies involved [31] Group 5: Public Company Acquisitions - A total of 22 publicly listed companies were acquired in Q1 2025, indicating a shift in control for these firms [8][32] - Notable transactions included two "A and A" deals and one "A and H" deal, highlighting the ongoing consolidation in the market [8][32] Group 6: Acquisition Methods and Buyer Intentions - Agreement-based acquisitions remained the dominant method, accounting for 78.93% of transactions, followed by share issuance for asset purchases at 8.38% [10][34] - The primary motive for acquisitions was horizontal integration, representing 63.49% of the transactions, aimed at market expansion and long-term development [12][36] Group 7: Institutional Participation and Exits - Institutions participated in 58 acquisition transactions, primarily in sectors like healthcare, energy, and automotive [14][38] - Notable exits included 47 transactions involving institutional investors, with significant activity in energy and automotive sectors [16][40]

Group 1 - A total of 26 companies were investigated by institutions on May 26, with 20 companies specifically targeted by funds [1] - The most popular company among funds was Cankin Technology, which had 13 participating funds, followed by Greebo and Hars, each with 12 funds [1] - The companies investigated belong to various sectors, including electronics, machinery, basic chemicals, and pharmaceutical biology, with three stocks from each of these sectors being highlighted [1] Group 2 - Among the companies investigated, four had a total market capitalization exceeding 50 billion yuan, with BOE Technology Group being one of them, while ten companies had a market cap below 10 billion yuan [1] - In terms of market performance, eight stocks among the investigated companies saw an increase in the last five days, with Kailer Co., Zhongsheng Pharmaceutical, and Zhongchumei leading with increases of 21.62%, 7.52%, and 5.76% respectively [1] - Conversely, twelve stocks experienced declines, with Jiangnan Yifan, Tangyuan Electric, and Greebo showing the largest drops of 5.68%, 4.34%, and 3.89% respectively [1] Group 3 - The funds that participated in the investigations included significant net inflows, with Zhongsheng Pharmaceutical receiving a net inflow of 122 million yuan, the highest among the stocks [2] - Other companies with notable net inflows included Haida Group and Kailer Co., with net inflows of 36.68 million yuan and 11.77 million yuan respectively [2] - The table of companies investigated includes various details such as stock codes, latest closing prices, five-day price changes, and industry classifications [2][3]